Refractory Non-Hodgkin’s lymphoma presents unique challenges when the disease doesn’t respond to initial treatment or returns after a period of improvement, but advances in medical research continue to expand the range of options available to patients facing this difficult situation.

When Treatment Doesn’t Work as Expected

For many people diagnosed with Non-Hodgkin’s lymphoma, the journey begins with hope that standard treatments will eliminate the cancer cells. However, not all cases follow the same path. The primary goal when dealing with refractory Non-Hodgkin’s lymphoma is to control the disease, manage symptoms, and maintain the best possible quality of life. Treatment decisions depend heavily on several factors including the specific type of lymphoma, the extent of previous treatments received, overall health status, and whether the cancer is fast-growing or slow-developing.^[1]

Medical teams recognize that each person’s situation is unique. When lymphoma doesn’t respond to initial therapy or comes back after treatment, doctors rely on both well-established approaches that have been used successfully for years and newer experimental therapies being tested in clinical trials—carefully monitored research studies that evaluate promising new treatments. These clinical trials represent an important source of hope, offering access to cutting-edge therapies that might not yet be widely available.^[2]

Understanding the difference between medical terms can help patients navigate their diagnosis. The word refractory describes lymphoma that doesn’t respond adequately to treatment, meaning the cancer cells continue growing or don’t shrink as expected. Some doctors consider lymphoma refractory if the response to treatment doesn’t last very long. This differs from relapsed lymphoma, which refers to disease that returns after a period of remission—when tests and scans show no evidence of cancer for at least six months following treatment.^[1][8]

Established Treatment Approaches for Refractory Disease

When Non-Hodgkin’s lymphoma proves resistant to initial therapy, doctors turn to several well-established treatment strategies. The choice depends on whether the lymphoma is classified as low-grade (slow-growing) or high-grade (fast-growing), as these categories behave quite differently and require distinct approaches.^[3]

Chemotherapy Regimens for Resistant Lymphoma

For patients whose lymphoma returns or doesn’t respond to first-line treatment, several second-line chemotherapy regimens are available. These combination treatments use different drugs than those tried initially, often in more intensive doses. Common regimens include combinations known by their abbreviations: ICE (ifosfamide, carboplatin, and etoposide), DHAP (dexamethasone, cisplatin, and cytarabine), and gemcitabine-based therapy. Each of these combinations works by attacking cancer cells through different mechanisms.^[4][11]

Another approach pairs the chemotherapy drug bendamustine with rituximab, a monoclonal antibody—a laboratory-made protein designed to attach to specific targets on cancer cells. Rituximab specifically targets a protein called CD20 found on the surface of B cells, which are the lymphocytes affected in most Non-Hodgkin’s lymphomas. This combination has shown effectiveness in controlling relapsed disease.^[4]

When lymphoma doesn’t improve with standard-dose chemotherapy, doctors may recommend high-dose chemotherapy. This intensive approach uses much stronger doses of cancer-killing drugs. However, these high doses can severely damage bone marrow—the spongy tissue inside bones where blood cells are made. This damage interferes with the body’s ability to produce healthy blood cells, leading to serious complications including extreme fatigue, breathlessness, increased vulnerability to infections, and excessive bleeding or bruising. To overcome this problem, high-dose chemotherapy must be followed by a stem cell or bone marrow transplant to replace the damaged bone marrow.^[3][10]

Stem Cell Transplantation

High-dose chemotherapy followed by stem cell transplantation represents a potentially curative option for patients with refractory or relapsed diffuse large B-cell lymphoma, the most common aggressive form of Non-Hodgkin’s lymphoma. In most cases, patients undergo an autologous transplant, where their own stem cells are collected before the intensive chemotherapy begins and then returned to their body afterward. Less commonly, patients may receive an allogeneic transplant using stem cells from a donor.^[4][11]

The transplantation process requires careful planning and monitoring. Before the high-dose chemotherapy, healthy stem cells are removed from the patient’s blood and frozen for safekeeping. After the intensive chemotherapy destroys both cancer cells and bone marrow, the stored stem cells are thawed and infused back into the patient’s bloodstream. Over time, these stem cells travel to the bone marrow and begin producing new, healthy blood cells. This recovery process takes several weeks, during which patients remain vulnerable to infections and require close medical supervision, typically in a specialized transplant center.^[14]

Radiotherapy for Refractory Cases

Radiation therapy can play a role in treating refractory Non-Hodgkin’s lymphoma, particularly when the disease remains confined to one area of the body or when specific tumors are causing symptoms. This treatment uses high-energy rays to damage cancer cells and stop them from growing. Sessions are typically short and given daily, Monday through Friday, usually for no more than three weeks. Patients don’t need to stay in hospital between appointments.^[3][10]

The side effects of radiotherapy vary depending on which part of the body receives treatment. For example, radiation to the throat may cause soreness and difficulty swallowing, while treatment to the head can lead to temporary hair loss in the treated area. Common effects include redness and soreness of the skin where the radiation beam passes through, tiredness that may persist for weeks, and occasionally nausea. Most side effects gradually improve once treatment finishes.^[3]

Active Monitoring for Low-Grade Lymphoma

When refractory lymphoma is low-grade and not causing troublesome symptoms, doctors may recommend a period of active monitoring, also called “watch and wait.” This approach recognizes that some people with slow-growing lymphoma can live well for many years without treatment. During active monitoring, patients attend regular check-ups where doctors examine them and ask about symptoms. Treatment begins only when symptoms develop or worsen. This strategy helps avoid unnecessary side effects from treatment when the disease isn’t causing problems.^[3][8]

Innovative Therapies Being Tested in Clinical Trials

While conventional treatments have improved outcomes for many patients with refractory Non-Hodgkin’s lymphoma, research continues to develop and test new approaches. Clinical trials represent the frontier of cancer treatment, offering patients access to therapies that may become tomorrow’s standard care.^[2]

CAR T-Cell Therapy: Harnessing the Immune System

One of the most promising advances in treating refractory Non-Hodgkin’s lymphoma is CAR T-cell therapy, a sophisticated form of immunotherapy that helps the immune system recognize and destroy cancer cells. This treatment has shown remarkable potential for achieving lasting remissions in patients whose lymphoma hasn’t responded to other therapies.^[2][9]

CAR T-cell therapy works by modifying a patient’s own immune cells. First, doctors collect T cells—a type of white blood cell that normally fights infections—from the patient’s blood. These cells are then sent to a specialized laboratory where they are genetically engineered to produce special receptors on their surface called chimeric antigen receptors, or CARs. These engineered receptors enable the T cells to recognize specific proteins on lymphoma cells. The modified T cells are grown in large numbers in the laboratory and then infused back into the patient, where they seek out and attack the cancer.^[4][11]

Several CAR T-cell products have received approval for treating relapsed or refractory Non-Hodgkin’s lymphoma. These include axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi), and tisagenlecleucel (Kymriah). These therapies target CD19, a protein found on the surface of B cells and most B-cell lymphomas. Clinical trials have demonstrated that CAR T-cell therapy can provide the potential for cure in some patients with aggressive lymphomas that have resisted other treatments.^[4][11]

However, CAR T-cell therapy can cause significant side effects. The most serious is cytokine release syndrome, which occurs when the modified T cells multiply rapidly and release large amounts of inflammatory proteins into the bloodstream, potentially causing high fever, low blood pressure, and difficulty breathing. Another concern is neurological effects, which can include confusion, difficulty speaking, and in severe cases, seizures. These complications require careful monitoring in specialized treatment centers experienced in managing CAR T-cell therapy.^[2]

Targeted Antibody Therapies

Beyond CAR T-cells, researchers are developing and testing numerous other antibody-based treatments for refractory lymphoma. Several targeted drugs have become available for second-line treatment, offering new options when initial therapies fail. These include polatuzumab vedotin-piiq (Polivy), tafasitamab-cxix (Monjuvi), epcoritamab-bysp (Epkinly), and glofitamab-gxbm (Columvi).^[4][11]

These agents work through different mechanisms. Some are antibody-drug conjugates, which combine a monoclonal antibody with a powerful chemotherapy drug. The antibody portion seeks out specific proteins on lymphoma cells, delivering the attached chemotherapy directly to the cancer while sparing normal cells from unnecessary exposure to the toxic drug. Others are bispecific antibodies that can simultaneously attach to proteins on both lymphoma cells and T cells, bringing the immune cells close to the cancer to facilitate its destruction.^[2][12]

Small Molecule Inhibitors and Oral Therapies

Another category of novel treatments includes oral medications that target specific pathways cancer cells use to grow and survive. These tyrosine kinase inhibitors and other small molecules can be taken at home as pills, offering a more convenient alternative to intravenous therapies. Examples include lenalidomide combined with rituximab, ibrutinib, and other drugs that interfere with molecular signals inside lymphoma cells.^[2][9]

Lenalidomide (Revlimid) is an immunomodulatory drug that affects the immune system and has direct effects on cancer cells. When combined with rituximab, it has shown activity against certain types of relapsed lymphoma. Ibrutinib and other Bruton tyrosine kinase (BTK) inhibitors block a specific enzyme that helps lymphoma cells survive and multiply. These drugs have demonstrated effectiveness particularly in certain subtypes of Non-Hodgkin’s lymphoma.^[2][4]

Selinexor (Xpovio) represents yet another mechanism of action. This drug blocks a protein that normally helps lymphoma cells export tumor-suppressor proteins out of the cell nucleus. By keeping these protective proteins inside the nucleus where they belong, selinexor can trigger cancer cell death. It has received approval for use in certain relapsed or refractory lymphomas.^[4]

Engineered Natural Killer Cell Therapies

Beyond T cells, researchers are exploring the use of engineered natural killer (NK) cells for treating refractory lymphoma. NK cells represent the body’s first line of defense against cancer, naturally targeting and destroying abnormal cells. In clinical trials, scientists are testing NK cells that have been modified to be even more effective at killing cancer.^[7]

One such trial, known as QUILT 3.092, is testing a combination approach for patients with relapsed or refractory B-cell Non-Hodgkin’s lymphoma. This Phase 1 study evaluates CD19-targeted high-affinity NK cells (CD19 t-haNK), which have been engineered to specifically seek out lymphoma cells bearing the CD19 protein. These cells are being tested both alone and in combination with N-803, a drug that activates both NK cells and T cells to enhance their cancer-fighting abilities, plus rituximab. The study aims to enroll up to 20 participants and focuses primarily on assessing safety, though researchers will also measure anti-cancer effects.^[7]

To participate in this trial, patients must be 18 years or older with relapsed or refractory B-cell Non-Hodgkin’s lymphoma that expresses both CD19 and CD20 proteins and persists after at least two attempts at chemotherapy. Participants should have previously received rituximab or another anti-CD20 antibody and either undergone autologous transplantation or been ineligible for this procedure. The treatment involves receiving CD19 t-haNK cells over the first four weeks, followed by additional weeks of treatment with or without N-803, for a total of approximately 15 weeks, with follow-up lasting a year.^[7]

Checkpoint Inhibitors for Specific Subtypes

For patients with certain subtypes of refractory lymphoma, particularly primary mediastinal large B-cell lymphoma (PMBCL), immune checkpoint inhibitors represent another treatment option. Pembrolizumab (Keytruda) is an example of this class of drugs. These medications work by blocking proteins that prevent the immune system from attacking cancer cells. By releasing this “brake” on the immune system, checkpoint inhibitors allow T cells to recognize and destroy lymphoma cells more effectively.^[4][11]

Understanding Clinical Trial Phases

When evaluating potential participation in clinical trials, it helps to understand how new treatments are tested. Clinical trials progress through several phases, each with specific goals. Phase I trials primarily assess safety, determining the appropriate dose and identifying side effects in a small group of patients. Phase II trials evaluate whether the treatment shows effectiveness against the disease while continuing to monitor safety in a larger group. Phase III trials compare the new treatment directly against standard therapy to determine if it offers superior results, involving hundreds or thousands of participants.^[2]

Many clinical trials for refractory Non-Hodgkin’s lymphoma are conducted at major cancer centers across the United States, Europe, and other regions. Eligibility criteria vary by study but typically consider factors such as the specific type and stage of lymphoma, previous treatments received, overall health status, and organ function. Patients interested in clinical trials should discuss options with their oncology team, who can help identify appropriate studies and explain the potential benefits and risks.^[2]

Most common treatment methods

• Chemotherapy regimens
  • ICE: combination of ifosfamide, carboplatin, and etoposide
  • DHAP: combination of dexamethasone, cisplatin, and cytarabine
  • Gemcitabine-based therapy
  • Bendamustine plus rituximab
  • High-dose chemotherapy followed by stem cell transplant
• Targeted monoclonal antibodies
  • Rituximab combined with various chemotherapy drugs
  • Polatuzumab vedotin-piiq (Polivy): antibody-drug conjugate
  • Tafasitamab-cxix (Monjuvi): anti-CD19 antibody
  • Epcoritamab-bysp (Epkinly): bispecific antibody
  • Glofitamab-gxbm (Columvi): bispecific antibody
• CAR T-cell immunotherapy
  • Axicabtagene ciloleucel (Yescarta): engineered T cells targeting CD19
  • Lisocabtagene maraleucel (Breyanzi): engineered T cells targeting CD19
  • Tisagenlecleucel (Kymriah): engineered T cells targeting CD19
• Small molecule inhibitors
  • Lenalidomide (Revlimid) plus rituximab: immunomodulatory combination
  • Ibrutinib: Bruton tyrosine kinase (BTK) inhibitor
  • Selinexor (Xpovio): nuclear export inhibitor
• Stem cell transplantation
  • Autologous transplant: using patient’s own stem cells
  • Allogeneic transplant: using donor stem cells
• Radiotherapy
  • External beam radiation for localized disease or symptom control
  • Short daily sessions typically lasting up to three weeks
• Checkpoint inhibitors
  • Pembrolizumab (Keytruda) for primary mediastinal large B-cell lymphoma
• Experimental cellular therapies in trials
  • Engineered natural killer (NK) cells targeting CD19
  • NK cell activators like N-803 in combination with other treatments